As mag­ni­tude and fre­quen­cy of drug price hikes thaw, Ex­press Scripts re­ports low­est in­crease in spend­ing by com­mer­cial plans in 25 years

In an era where drug­mak­ers and pre­scrip­tion drug man­agers (PBMs) point fin­gers at each oth­er when it comes to jus­ti­fy­ing the rea­sons be­hind ris­ing drug prices — the largest US PBM, Ex­press Scripts, on Wednes­day re­leased a re­port in­di­cat­ing that in 2018 em­ploy­er-spon­sored plans paid rough­ly 6 cents more, on av­er­age, for a 30-day pre­scrip­tion (0.4% hike) ver­sus the pre­ced­ing year, mark­ing the small­est in­crease in com­mer­cial plans in a quar­ter cen­tu­ry.

The com­pa­ny an­a­lyzed pre­scrip­tion drug use da­ta of rough­ly 34.2 mil­lion mem­bers with a phar­ma­cy ben­e­fit plan and cal­cu­lat­ed that it had saved its mem­bers $45 bil­lion in pre­scrip­tion drug costs in 2018.

Al­though spend­ing on tra­di­tion­al, non-spe­cial­ty med­ica­tions dipped 5.8%, spend­ing on spe­cial­ty med­ica­tions rose 9.4%, Ex­press Scripts said. Drugs for in­flam­ma­to­ry con­di­tions such as rheuma­toid arthri­tis and Crohn’s dis­ease ac­count­ed for the costli­est ther­a­py class for the third con­sec­u­tive year, cost­ing em­ploy­ers $174.45 per mem­ber per year in 2018, up 14% from 2017, it added. Glob­al­ly, Ab­b­Vie’s in­flam­ma­to­ry drug Hu­mi­ra — the world’s best-sell­ing med­i­cine — gen­er­at­ed near­ly $20 bil­lion in 2018 sales.

Di­a­betes was the sec­ond costli­est ther­a­py class for em­ploy­ers at $114.85 per mem­ber per year, an in­crease of 4.1% over 2017, the com­pa­ny said, adding that spend­ing on in­sulin, which ac­counts for 15.3% of di­a­betes pre­scrip­tions, rose 0.3% in 2018 (a 1.5% de­cline in unit costs and a 1.8% rise in uti­liza­tion). Anec­do­tal re­ports of di­a­bet­ics ra­tioning or for­go­ing life-sav­ing in­sulin in the Unit­ed States are on the rise.

For a long time drug­mak­ers jus­ti­fied their pol­i­cy of sus­tained drug price hikes on the heavy cost of in­no­va­tion. How­ev­er, as PBMs in­creas­ing­ly threat­en to ex­clude treat­ments from for­mu­la­ries — un­less they man­age to ne­go­ti­ate a dis­count sat­is­fac­to­ry to their de­mands — drug­mak­ers in re­sponse have boost­ed re­bates, and in turn hiked prices in or­der to main­tain their cut of sales.

De­spite list price in­fla­tion of 7.3% for the most com­mon­ly used tra­di­tion­al brand med­ica­tions in 2018, costs for such drugs dipped 6.5% for its em­ploy­er-spon­sored plans, Ex­press Scripts said.

The com­pa­ny has dri­ven a 0.4% de­cline in drug unit costs by steer­ing mem­bers to low­er cost ther­a­pies, and by se­cur­ing deep­er dis­counts from man­u­fac­tur­ers and phar­ma­cies, it said, adding that about half of com­mer­cial plans saw a fall in per mem­ber drug spend­ing, and a 0.3% de­cline across Medicare plans.

Twen­ty five years ago, the era of block­buster drugs was tak­ing off, char­ac­ter­ized by mid-to-high-dou­ble-dig­it an­nu­al in­creas­es in drug spend­ing, the com­pa­ny said, not­ing that to­day we are in the age of break­through treat­ments with “break-the-bank pric­ing.”

“We ex­pect man­u­fac­tur­ers of high-priced spe­cial­ty drugs, which cur­rent­ly con­sume half of all drug spend­ing, to con­tin­ue to raise prices faster than core in­fla­tion. And we ex­pect the con­tentious pub­lic pol­i­cy de­bate on how to make pre­scrip­tion med­i­cine, and es­pe­cial­ly in­sulin and oth­er bi­o­log­ics, more af­ford­able for the unin­sured and un­der­in­sured to con­tin­ue,” the com­pa­ny said, fore­cast­ing an an­nu­al drug trend of 2% for the next three years.

Da­ta in­creas­ing­ly sug­gest that pric­ing is con­tribut­ing to a small­er slice of bio­phar­ma growth than ever be­fore. In a note pub­lished ear­li­er this week, Leerink’s Ge­of­frey Porges said “pos­i­tive list pric­ing has con­tributed at least two thirds of in­dus­try growth in re­cent years and this con­tri­bu­tion ap­pears to be fad­ing, if not dis­ap­pear­ing…in many strik­ing cas­es we are see­ing sig­nif­i­cant ab­solute re­duc­tions in price, which was pre­vi­ous­ly un­think­able for this in­dus­try.” For ex­am­ple, PC­SK9 an­ti­bod­ies by Am­gen as well as part­ners Sanofi and Re­gen­eron have re­cent­ly seen heavy dis­counts, while CGRP an­ti­bod­ies from Te­va, Lil­ly as well as part­ners Am­gen and No­var­tis have tak­en a large­ly con­ser­v­a­tive ap­proach to pric­ing.

Drug pric­ing has emerged as a bi­par­ti­san is­sue and a host of law­mak­ers, in­clud­ing those rep­re­sent­ing the Trump ad­min­is­tra­tion, have pro­posed a num­ber of so­lu­tions to low­er the bur­den of drug costs on con­sumers.


Slides from Ex­press Scripts re­port

MedTech clinical trials require a unique regulatory and study design approach and so engaging a highly experienced CRO to ensure compliance and accurate data across all stages is critical to development milestones.

In­no­v­a­tive MedTech De­mands Spe­cial­ist Clin­i­cal Tri­al Reg­u­la­to­ry Af­fairs and De­sign

Avance Clinical is the Australian CRO for international biotechs providing world-class clinical research services with FDA-accepted data across all phases. With Avance Clinical, biotech companies can leverage Australia’s supportive clinical trials environment which includes no IND requirement plus a 43.5% Government incentive rebate on clinical spend. The CRO has been delivering clinical drug development services for international biotechs for FDA and EMA regulatory approval for the past 24 years. The company has been recognized for the past two consecutive years with the prestigious Frost & Sullivan CRO Best Practices Award and a finalist in Informa Pharma’s Best CRO award for 2022.

Gold for adults, sil­ver for in­fants: Pfiz­er's Pre­vnar 2.0 head­ed to FDA months af­ter Mer­ck­'s green light

Pfizer was first to the finish line for the next-gen pneumococcal vaccine in adults, but Merck beat its rival with a jab for children in June.

Now, two months after Merck’s 15-valent Vaxneuvance won the FDA stamp of approval for kids, Pfizer is out with some late-stage data on its 20-valent shot for infants.

Known as Prevnar 20 for adults, Pfizer’s 20vPnC will head to the FDA by the end of this year for an approval request in infants, the Big Pharma said Friday morning. Discussions with the FDA will occur first and more late-stage pediatric trials are expected to read out soon, informing the regulatory pathway in other countries and regions.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 147,600+ biopharma pros reading Endpoints daily — and it's free.

Senate Finance Committee Chair Ron Wyden (D-OR) (Francis Chung/E&E News/POLITICO via AP Images)

Sen­ate Fi­nance Chair con­tin­ues his in­ves­ti­ga­tion in­to phar­ma tax­es with re­quests for Am­gen

Amgen is the latest pharma company to appear on the radar of Senate Finance Committee Chair Ron Wyden (D-OR), who is investigating the way pharma companies are using subsidiaries in low- or zero-tax countries to lower their tax bills.

Like its peers Merck, AbbVie and Bristol Myers Squibb, Wyden notes how Amgen uses its Puerto Rico operations to consistently pay tax rates that are substantially lower than the U.S. corporate tax rate of 21%, with an effective tax rate of 10.7% in 2020 and 12.1% in 2021.

FDA ap­proves sec­ond in­di­ca­tion for As­traZeneca and Dai­ichi's En­her­tu in less than a week

AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu scored its second approval in less than a week, this time for a subset of lung cancer patients.

Enhertu received accelerated approval on Thursday to treat adults with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, and who have already received a prior systemic therapy.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 147,600+ biopharma pros reading Endpoints daily — and it's free.

Pharma brands are trying to figure out new ways to better reach patients and doctors, but also measure results. (Credit: Shutterstock)

Do phar­ma TV and so­cial ads work? Phar­ma mar­ket­ing agen­cies adopt­ing new tech so­lu­tions to find out

It’s a timeworn advertising question — is my ad campaign working? In pharma, that can be an especially difficult question to answer in part because of privacy regulations, but also because the brands spend a lot of money on TV commercials where viewers can’t directly click on an ad.

Healthcare marketing services companies like Lasso and CMI Media Group are trying to change that with new measurement methods and partnerships that aim to get closer to patients’ and physicians’ actions.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 147,600+ biopharma pros reading Endpoints daily — and it's free.

Corey McCann, Pear Therapeutics CEO

Pear Ther­a­peu­tics touts Q2 growth while scal­ing back full-year goals and chop­ping 9% of staff

Pear Therapeutics set some ambitious goals back in March, predicting a five-fold boost in revenue and a surge in new prescriptions for its digital therapeutics. Now the company is scaling back those estimates and chopping 9% of its workforce — an all-too-common occurrence in biotech lately.

CEO Corey McCann unveiled Pear’s Q2 numbers on Thursday, touting a 20% quarter-over-quarter revenue growth totaling $3.3 million. That’s more than double what the company made in Q2 2021, and McCann thinks the team could see a nearly four-fold jump in revenue this year, falling in the range of $14 million to $16 million.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 147,600+ biopharma pros reading Endpoints daily — and it's free.

Seagen interim CEO Roger Dansey and Daiichi Sankyo CEO Sunao Manabe

Paving the way for Mer­ck­'s buy­out, Seagen los­es ar­bi­tra­tion dis­pute with Dai­ichi over ADC tech

As Seagen awaits a final buyout offer from Merck that could be in the territory of $40 billion, Seagen revealed Friday afternoon that it lost an arbitration dispute with Daiichi Sankyo relating to the companies’ 2008 collaboration around the use of antibody-drug conjugate (ADC) technology.

But that loss likely won’t matter much when it comes to Merck’s deal.

After breaking off its pact with Daiichi in mid-2015, the two companies battled over “linker” tech — a chemical bridge between an ADC’s antibody component and the cytotoxic payload — that Seagen claims Daiichi would improve upon and implement in its current generation of ADCs.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 147,600+ biopharma pros reading Endpoints daily — and it's free.

J&J to re­move talc prod­ucts from shelves world­wide, re­plac­ing with corn­starch-based port­fo­lio

After controversially spinning out its talc liabilities and filing for bankruptcy in an attempt to settle 38,000 lawsuits, Johnson & Johnson is now changing up the formula for its baby powder products.

J&J is beginning the transition to an all cornstarch-based baby powder portfolio, the pharma giant announced on Thursday — just months after a federal judge ruled in favor of its “Texas two-step” bankruptcy to settle allegations that its talc products contained asbestos and caused cancer. An appeals court has since agreed to revisit that case.

CSL is gathering its four business units under a unified brand identity strategy (Credit: CSL company site)

CSL brings Se­qirus, Vi­for un­der par­ent um­brel­la brand in iden­ti­ty re­vamp

CSL is gathering its brands under the family name umbrella, renaming its vaccine and newly acquired nephrology specialty businesses with the parent initials.

CSL Seqirus and CSL Vifor join CSL Plasma and CSL Behring as the four now uniformly branded business units of the global biopharma. The Seqirus vaccine division was formed in 2015 with the combination of bioCSL and its purchase of Novartis’ flu vaccine business. CSL picked up Vifor Pharma late last year in an $11.7 billion deal for the nephrology, iron deficiency and cardio-renal drug developer.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 147,600+ biopharma pros reading Endpoints daily — and it's free.